RBRP_HUMAN
ID RBRP_HUMAN Reviewed; 71 AA.
AC C0HM01;
DT 25-MAY-2022, integrated into UniProtKB/Swiss-Prot.
DT 25-MAY-2022, sequence version 1.
DT 03-AUG-2022, entry version 2.
DE RecName: Full=Putative RNA-binding regulatory peptide {ECO:0000305};
DE Short=RBRP {ECO:0000303|PubMed:32245947};
DE AltName: Full=Septin 14 pseudogene 20 {ECO:0000312|HGNC:HGNC:51706};
GN Name=SEPTIN14P20 {ECO:0000312|HGNC:HGNC:51706};
GN Synonyms=C20orf69 {ECO:0000312|HGNC:HGNC:51706},
GN LINC00266-1 {ECO:0000303|PubMed:32245947};
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1] {ECO:0000305}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=11780052; DOI=10.1038/414865a;
RA Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT "The DNA sequence and comparative analysis of human chromosome 20.";
RL Nature 414:865-871(2001).
RN [2] {ECO:0000305}
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [3] {ECO:0000305}
RP IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, INTERACTION WITH IGF2BP1,
RP TISSUE SPECIFICITY, AND MUTAGENESIS OF GLY-19 AND GLY-63.
RX PubMed=32245947; DOI=10.1038/s41467-020-15403-9;
RA Zhu S., Wang J.Z., Chen D., He Y.T., Meng N., Chen M., Lu R.X., Chen X.H.,
RA Zhang X.L., Yan G.R.;
RT "An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and
RT tumorigenesis.";
RL Nat. Commun. 11:1685-1685(2020).
CC -!- FUNCTION: Enhances binding of IGF2BP1 to N6-methyladenosine (m6A)-
CC containing mRNAs, thereby contributing to increased mRNA stability
CC (PubMed:32245947). Also increases the interaction of IGF2BP1 with RNA
CC stabilizers ELAVL1/HUR, MATR3 and PABPC1, and increases the interaction
CC of RNA stabilizers ELAVL1/HUR, MATR3 and PABPC1 with m6A-containing
CC mRNAs (PubMed:32245947). Contributes to MYC stability by enhancing
CC binding of IGF2BP1 to m6A-containing MYC mRNAs and increasing
CC recruitment of RNA stabilizing proteins to m6A-containing MYC mRNAs
CC (PubMed:32245947). {ECO:0000269|PubMed:32245947}.
CC -!- SUBUNIT: Interacts with IGF2BP1 (via KH3 and KH4 domains); the
CC interaction results in increased binding of IGF2BP1 to N6-
CC methyladenosine (m6A)-containing mRNAs. {ECO:0000269|PubMed:32245947}.
CC -!- TISSUE SPECIFICITY: Detected in colon (at protein level).
CC {ECO:0000269|PubMed:32245947}.
CC -!- MISCELLANEOUS: Promotes colon cancer cell growth, colony formation,
CC migration and invasion through enhanced stability of MYC
CC (PubMed:32245947). Expressed in colorectal, breast, ovarian and
CC nasopharyngeal cancer cells (PubMed:32245947). Higher levels are found
CC in colon cancer cells than in adjacent nontumor tissue
CC (PubMed:32245947). {ECO:0000269|PubMed:32245947}.
CC -!- CAUTION: Could be the product of a pseudogene. {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AL137028; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC118988; AAI18989.1; -; mRNA.
DR EMBL; BC122537; AAI22538.1; -; mRNA.
DR HGNC; HGNC:51706; SEPTIN14P20.
DR Proteomes; UP000005640; Unplaced.
DR GO; GO:0048255; P:mRNA stabilization; IDA:UniProtKB.
DR GO; GO:1902416; P:positive regulation of mRNA binding; IDA:UniProtKB.
PE 5: Uncertain;
KW Reference proteome.
FT CHAIN 1..71
FT /note="Putative RNA-binding regulatory peptide"
FT /id="PRO_0000455125"
FT MUTAGEN 19
FT /note="G->A: Abolishes binding to IGF2BP1 and does not
FT increase binding of IGF2BP1 to m6A-containing RNAs or to
FT RNA stabilizers ELAVL1/HUR, MATR3 or PABPC1."
FT /evidence="ECO:0000269|PubMed:32245947"
FT MUTAGEN 63
FT /note="G->A: No effect on binding to IGF2BP1."
FT /evidence="ECO:0000269|PubMed:32245947"
SQ SEQUENCE 71 AA; 8407 MW; 0C5F6A265B8B887F CRC64;
MIQQEEIRKL EEEKKQLEGE IIDFYKMKAA SEALQTQLST DTKKDKHPDP YEFLLLRKIK
HPGFNEELSP C
